Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase Ib/IIa clinical trial to combine the CSF1 receptor inhibitor pexidartinib with the androgen receptor antagonist enzalutamide in metastatic castration resistant prostate cancer

Trial Profile

A phase Ib/IIa clinical trial to combine the CSF1 receptor inhibitor pexidartinib with the androgen receptor antagonist enzalutamide in metastatic castration resistant prostate cancer

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 09 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pexidartinib (Primary) ; Enzalutamide
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms POLERISE
  • Most Recent Events

    • 05 Apr 2019 Status changed from recruiting to discontinued.
    • 26 Mar 2019 Recruitment completion is expected on 30 Apr 2019, according to ISRCTN: Current Controlled Trials.
    • 07 Jun 2018 Planned initiation date changed from 1 Oct 2016 to 31 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top